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INTRODUCTION 
Trimetazidine Dihydrochloride is chemically described as 
1-(2, 3, 4-trimethoxybenzyl) piperazine. It is an energy 
metabolism of the cell exposed to hypoxia or ischemic, 
avoids the collapse of the intracellular level of adenosine 
triphosphate (ATP). It thus ensures the functioning of the 
ion pumps and the transmembrane flow of sodium-
potassium and maintains cellular homeostasis. It has been 
used in the form of its Dihydrochloride as a coronary 
vasodilator for the prophylactic treatment of angina 
pectoris crisis, its short biological half life (6 h) that calls 
for frequent daily dosing (2 to 3 times) and therapeutic use 
in angina pectoris crisis disease necessitates its formulat ion 
into modified release dosage form
1
. The development of 
Modified / Controlled release formulat ion of Trimetazidine 
Dihydrochloride is therefore of therapeutic relevance and 
can be used to provide a consistent dosage through 
sustaining an appropriate level o f drug over time.  The 
simplest and least expensive way to control the release of 
the drug is to disperse it within an inert polymeric matrix 
and hydrophilic matrices are an interesting option when 
formulat ing an oral modified release (MR) of a drug. The 
dosage release properties of matrix devices may be 
dependent upon solubility of the drug in the polymer 
matrix or, in case of porous matrices, the solubility in the 
sink solution within the particle’s pore network. 
Hydroxypropylmethylcellulose (HPMC) is the dominant 
hydrophilic vehicle used for the preparation of oral 
controlled drug delivery systems 
3
. Numerous studied have 
been reported in literature investigating the HPMC 
matrices to control the release of a variety of drugs from 
matrices. The objective of the present study was to 
formulate Trimetazidine Dihydrochloride MR Matrix 
tablets using HPMC K4M polymer and to elucidate the 
release kinetics of Trimetazidine Dihydrochloride from 
HPMC matrices. We attempted a systematic approach to 
develop twice daily modified release Trimetazidine 
Dihydrochloride matrix tablets. 
MATERIALS AND METHODS  
Trimetazidine Dihydrochloride was obtained from MJ 
BIOPHARM Pvt ltd, Mumbai, HPMC K4M, a grade of 
HPMC, was procured from MJ BIOPHARM Pvt ltd, 
Mumbai, Dibasic Calcium Phosphate (Anhydrous), was 
procured from MJ BIOPHARM Pvt ltd, Mumbai., 
Polyvinyl Pyrrolidone (PVP-K30),  Aerosil
R
 200 and 
Magnesium Stearate, was procured from MJ BIOPHARM 
Pvt ltd, Mumbai, Isopropyl Alcohol  was procured from 
Rankem, Delhi. Materials and excipients used in preparing 
tablets were IP grades. All other ingredients used 
throughout the study were of analytical grade and were 
used as received. 
 Preparation of matrix tablets:  
Matrix tablets, each containing 35.3 mg Trimetazidine 
Dihydrochloride, were prepared by wet granulation 
technique. The drug polymer concentration was developed 
to adjust drug release and to keep total weight of tablet 
constant for all the fabricated batches under experimental 
conditions of preparations. The total weight of the matrix 
tablets was 200 mg with different drug polymer (HPMC) 
concentration. A batch of 1000 tablets was prepared in 
each formula. The composition of tablets is shown in 
Table 1. Dibasic calcium phosphate (anhydrous) was 
incorporated as filler excipient to maintain tablet weight 
constant. This filler was incorporated also for 
counterbalance the faster solubility of the drug in presence 
of hydrophilic polymer and to provide a stable monolithic 
matrix. The ingredients Trimetazid ine Dihydrochloride, 
HPMC, Dibasic calcium phosphate (anhydrous) were 
passed through sieve no. 40 and mixed in a polybag. The 
powder blend was granulated using granulating fluid PVP-
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K30 dissolved in IPA and pass the wet mass through sieve 
no. 12. Dry the wet granules in a Tray dryer at 600°c for 1 
hour. Pass the dried granules through sieve no. 20. The 
granules was then lubricated with magnesium stearate, 
Aerosil
R
 200 pass through sieve no. 40 and compressed 
into tablets on a 16-station single rotary Cadmach machine 
using 8.0 mm S/C biconvex punches plain on both sides.    
Evaluation of tablets:  
The prepared matrix tablets were evaluated for hardness, 
weight variat ion, thickness, friability and drug content. 
Hardness of the tablets was tested using a strong-cobb 
hardness tester (Tab machine, Mumbai). Friability of the 
tablets was determined in a Roche friabilator (Campbell 
Electronics, Mumbai). The thickness of the tablets was 
measured by vernier callipers. Weight variation test was 
performed according to official method 9. Drug content for 
Trimetazidine Dihydrochloride was  carried out by 
measuring the absorbance of samples at 231 nm using 
Shimadzu 1201 UV/Vis spectrophotometer and comparing 
the drug content from a calibrated curve prepared with 
standard Trimetazidine Dihydrochloride in the same 
medium. 
In vi tro drug release studies: 
 The in vitro dissolution studied was carried out using USP 
24 dissolution apparatus type II [10] (Basket method) at 50 
rpm. Dissolution test was carried out for a total period of 
12 h using 0.1N HCl (pH 1.2) solution (900 ml) as 
dissolution medium at 37 ± 0.50 for 1 hr, and pH 6.8 
phosphate buffer solution (900 ml) minimum of 2 hrs. Ten 
millilitres of the sample was withdrawn at regular intervals 
and replace with the same volume pre-warm (37 ± 0.50) 
fresh dissolution medium. The samples withdrawn were 
filtered through 0.45µ membrane filter, and drug content in 
each sample was analyzed after suitable dilution by above-
mentioned spectrophotometer at 231 nm. The actual 
content in samples was read from a calibration curve 
prepared with standard Trimetazid ine Dihydrochloride.  
Stability studies:  
One selected fabricated tablet batch was strip packaged 
and kept at 400°c with 75%RH. Samples were withdrawn 
at 30 and 60 °c for evaluation of appearance, drug content 
and in vitro drug release.  
RES ULT AND DISCUSSION  
The result of hardness and friability of the prepared matrix 
tablets ranged from 7.0 to 8.5 and 0.12 to 0.31 
respectively. (Table 3). The tablet formulations in all the 
prepared batches contained Trimetazidine Dihydrochloride 
within 100 ± 5% of labelled content. As such, all the 
batches of the fabricated tablets were of good quality with 
regard to hardness, friability and drug content. All tablets 
complied with pharmacopoeial specifications for weight 
variation and friability. Trimetazid ine Dihydrochloride 
release from tablets was slow and extended over longer 
periods of time. The results of dissolution studies of 
formulat ions F-I to F-V are shown in fig. 1. Drug release 
from the matrix tablets was found to increase with 
decrease in drug polymer concentration. Formulat ion F-I 
and F-II composed of drug concentration release to 
sustained release after 12 h.   
Table 1: Formulae of Trimetazidine Dihydrochloride tablet 
 
Ingredients   (mg/tab) 
Formulations 
F-1 F-2 F-3 F-4 F-5 
Trimetazidine Dihydrochloride 36.4 36.4 36.4 36.4 36.4 
HPMCK4M 122 117 113 107 103 
Di-basicCalcium Phosphate (anhyd) 33 39 44 48 55 
PVPK30 5 5 5 5 5 
Aerosil 1 1 1 1 1 
Magnesium Stearate 6.1 6.1 6.1 6.1 6.1 
CPA  qs qs qs qs qs 
Total 200 200 200 200 200 
 
The release of drug depends not only on the nature of 
matrix but also the drug polymer concentration. As the 
percentage of polymer increased, the kinetics of release 
decreased. This may be due to structural reorganization of 
hydrophilic HPMC polymer. Increase in concentration of 
HPMC may result in increase in the tortuosity or gel 
strength of the polymer. When HPMC polymer is exposed 
to aqueous medium, it undergoes rapid hydration and chain 
relaxation to form v iscous gelatinous layer (gel layer). 
Failure to generate a uniform and coherent gel may cause 
slow drug release [11, 12].  In vitro release studies 
demonstrated that the release of Trimetazidine 
Dihydrochloride from all these formulated MR matrix 
tablets can generally be modified (fig. 1). According to 
commercial tablet, modified release profile of oral 
controlled release formulation of Trimetazidine 
Dihydrochloride should provide a release of 25-45% in 1 
h, 43-63% in 2 h, NLT 60% in 4 h and NLT 80% in 8 h. 
Formulat ion F-III tablet gave release profile close to the 
commercial modified release tablet needed for 
Trimetazidine Dihydrochloride (fig. 1).  The data for 
stability studies carried out for F-III batch at 400°c with 
75% RH for 60 d revealed that no considerable differences 
in drug content and dissolution rate were observed (Table 
4). It may be concluded from the present study that slow, 
controlled and complete release of Trimetazidine 
Dihydrochloride over a period of 12 h was obtained from 
matrix tablets (F-III). It is also evident from the results that 
formulat ion F-III is better system for twice-daily MR of 
Trimetazidine Dihydrochloride.   
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Table 2: Percentage of drug release 
Formulation No PERCENTAGE OF RELEAS E IN TIME (HRS) 
1Hr 2Hr 4Hr 6Hr 8Hr 10Hr 12Hr 
F1 33.43 48.60 70.50 83.48 91.56 96.34 99.54 
F2 35.34 49.12 72.34 86.41 92.66 97.37 99.65 
F3 39.42 50.59 80.78 92.06 97.15 100.60 100.99 
F4 40.41 51.53 81.92 91.31 96.54 97.82 99.92 
F5 41.10 51.67 82.43 92.57 97.63 99.12 100.12 
 
Table 3: Properties of compressed Trimetazidine dihydrochloride Matrix tablet  
Formulation Weight  
(mg) 
Hardness(kg/c
2
) Thickness(mm) Friabilit (% ) Drug 
Content 
(% ) 
F-1 200.1 6.0 3.7 0.31 99.54 
F-2 198.4 5.0 3.6 0.22 99.65 
F-3 202.0 8.2 3.1 0.18 100.99 
F-4 204.3 7.5 3.4 0.15 99.92 
F-5 201.4 7.5 3.3 0.12 100.12 
Values are expressed in ± S.D from 5 observations. 
Table 4: Stability studies of Formulated F-III batch tablet 
Parameter Initial Tablets Strip pack at 40º 
with75%RH 
 
Drug Content 
 
100.99 
30 days 60 days 
99.67 % 99.55 % 
Note: Each value represents an average of two values 
  
Figure 1: Percentage of drug release 
CONCLUS ION  
In the above view of findings it can be concluded that the 
combination of hydrophobic polymer and pH dependent 
polymer are better suited for site specific drug delivery  
system than hydrophobic polymer alone. A matrix design 
of this kind can serve as an alternative strategy to enteric 
film coating techniques commonly  employed for the 
design of delayed release systems.  
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